Intestinal Fistula Treatment Global Market Report 2025

The intestinal fistula treatment market size has grown strongly in recent years. It will grow from $25.27 billion in 2024 to $27.1 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth during the historic period can be attributed to the increased incidence of gastrointestinal disorders, the rising prevalence of malnutrition, the growing geriatric population, advancements in healthcare infrastructure, and increased healthcare spending.

The intestinal fistula treatment market size is expected to see strong growth in the next few years. It will grow to $35.35 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to the increasing adoption of telemedicine, rising disposable income, the growing prevalence of Crohn’s disease, an aging population, and a greater emphasis on personalized medicine. Key trends expected during this period include AI-powered diagnostic tools, advancements in biologics, the use of 3D printing in medical applications, integrated care models, and the adoption of wearable health monitoring devices.

The rising prevalence of gastrointestinal (GI) disorders is expected to significantly contribute to the growth of the intestinal fistula treatment market. GI disorders encompass a wide range of conditions that affect the digestive tract, causing symptoms such as pain, bloating, diarrhea, or constipation, which often require medical intervention. Factors such as poor dietary habits, stress, and mental health issues are contributing to the increasing incidence of these conditions. Intestinal fistula treatment is vital in managing such disorders by addressing abnormal intestinal connections. This treatment helps to close these connections, prevent infections, restore gut function, and reduce complications such as malnutrition and sepsis. For example, according to the Centers for Disease Control and Prevention (CDC) in September 2023, approximately 14.8 million adults in the United States are affected by ulcers, and there are 35.4 million doctor visits annually for digestive issues. As the prevalence of gastrointestinal disorders rises, the demand for effective intestinal fistula treatments grows accordingly.

The improvement in healthcare facilities is another key factor driving the growth of the intestinal fistula treatment market. Healthcare facilities, such as hospitals, clinics, and diagnostic centers, play a crucial role in treating and supporting patients with conditions such as intestinal fistulas. These facilities are improving due to factors such as increased investments in healthcare infrastructure, a focus on patient-centered care, population growth, and aging demographics. Enhanced healthcare facilities contribute to better patient outcomes by offering a combination of medical, surgical, and nutritional interventions for intestinal fistula treatment. This helps optimize care delivery, reduce complications, minimize hospital stays, and improve chronic condition management. For instance, in May 2023, the American Health Care Association reported a 0.591% increase in the number of hospitals in the United States, totaling 6,129 hospitals, which indicates a growing capacity to treat patients, including those requiring intestinal fistula management.

Innovative therapeutic approaches are also playing a pivotal role in advancing the intestinal fistula treatment market. One promising development is mesenchymal stem cell (MSC) therapy, which is being explored for treating refractory perianal fistulas. MSC therapy involves using stem cells to promote tissue healing and regeneration, making it a potential treatment for autoimmune diseases, osteoarthritis, and gastrointestinal disorders. For example, in March 2022, Ossium Health Inc. received an Investigational New Drug (IND) application approval from the U.S. Food and Drug Administration (FDA) for OSSM-001, a mesenchymal stem cell product. This approval enabled the company to proceed with a multi-center Phase 1 clinical trial to assess the safety and feasibility of MSC therapy for fistula healing. The trial is designed to evaluate the safety profile and healing outcomes of this innovative therapy, offering new hope for patients with difficult-to-treat fistulas.

Major players in the intestinal fistula treatment market are Merck & Co. KGaA, Bristol-Myers Squibb, AstraZeneca plc, Pfizer Inc., Medtronic plc, Medtronic plc, Eli Lilly and Company, Moderna Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH, Cook Group Incorporated, Integra LifeSciences, Avante Health Solutions, Angiplast Pvt. Ltd., Angiplast Pvt. Ltd., Biolitec AG, Sklar Surgical Instruments, Livealth BioPharma, Surtex Instruments Limited, Advin Health Care.

North America was the largest region in the Intestinal Fistula Treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in intestinal fistula treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the intestinal fistula treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Intestinal fistula treatment involves the medical and surgical management of abnormal connections (fistulas) that develop between the intestine and other organs or the skin. Treatment approaches are determined based on the type, location, and severity of the fistula, along with the patient’s overall health and the underlying cause of the condition.

The primary treatment options for intestinal fistulas include medications, surgery, nutritional support, and other supportive therapies. Medications are used to manage symptoms and promote healing, administered through various routes such as oral, rectal, and parenteral. These treatments are distributed through multiple channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and are utilized by various end-users, such as hospitals, ambulatory surgical centers, and specialty clinics.

The intestinal fistula treatment market research report is one of a series of new reports that provides intestinal fistula treatment market statistics, including the intestinal fistula treatment industry global market size, regional shares, competitors with the intestinal fistula treatment market share, detailed intestinal fistula treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the intestinal fistula treatment industry. This intestinal fistula treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The intestinal fistula treatment market consists of revenues of services of medical management, and supportive therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The intestinal fistula treatment market also includes sales of anti-inflammatory drugs, metronidazole, ciprofloxacin and levofloxacin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.